BioDlink Ships First Bevacizumab to Colombia, Expanding Access

BioDlink has successfully completed its first international shipment of bevacizumab, a biosimilar injection, to Colombia in collaboration with Kexing BioPharm. This significant milestone was celebrated during a ceremony marking the arrival of specially-decorated transport vehicles in Suzhou, China, on October 27, 2025.

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and is widely utilized in oncology for conditions such as metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC). According to industry reports, bevacizumab generated global sales of approximately USD 8.5 billion in 2023.

Regulatory Milestone and Timely Delivery

In July 2025, BioDlink received marketing approval for its bevacizumab injection from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA). The inaugural shipment, dispatched merely two months after this approval, highlights BioDlink’s operational efficiency and the effectiveness of its antibody commercialization platform. The company has demonstrated robust production quality and effective supply chain management systems.

BioDlink’s manufacturing facilities span 50,000 square meters and have successfully passed EU Qualified Person (QP) audits for antibody drugs and antibody-drug conjugates (ADCs) five times over the past four years, with no critical defects reported. This quality assurance underpins the company’s capacity to deliver high-standard biopharmaceutical products.

Kexing BioPharm, which holds the global license for bevacizumab in emerging markets, has made significant strides in regulatory filings across 35 countries. The company has also secured Good Manufacturing Practice (GMP) certification in Colombia, Brazil, and Argentina, which collectively account for 71.4% of South America’s population.

Addressing Cancer Challenges in Colombia

Colombia faces a significant cancer burden, reporting 117,620 new cases in 2022, including 11,163 colorectal and 7,196 lung cases, according to GLOBOCAN 2022 data. The introduction of bevacizumab is strategically important, given its application in treating metastatic colorectal cancer and non-squamous non-small cell lung cancer.

Since formalizing their international commercialization agreement in early 2022, BioDlink and Kexing BioPharm have developed a synergistic “R&D-manufacturing-access” model. This framework positions them well for future product launches across international markets. BioDlink is committed to maintaining a robust manufacturing and supply chain, while Kexing BioPharm leverages its global reach to facilitate localized market access.

Both companies prioritize a shared mission to enhance global healthcare access. BioDlink adheres to its service philosophy of “Quality First, Innovation Driven, Success Together,” focusing on emerging markets in South America, South Asia, Southeast Asia, and Africa. This commitment aims to benefit a broader global patient population moving forward.

For further information on BioDlink and its initiatives, visit their website at [BioDlink](https://www.biodlink.com/).